Frequency Therapeutics, Inc. (FREQ)
| Market Cap | 1.31B |
| Revenue (ttm) | 31.74M |
| Net Income (ttm) | -21.81M |
| Shares Out | 33.07M |
| EPS (ttm) | -10.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $38.73 |
| Previous Close | $35.80 |
| Change ($) | 2.93 |
| Change (%) | 8.18% |
| Day's Open | 35.97 |
| Day's Range | 34.57 - 39.80 |
| Day's Volume | 214,094 |
| 52-Week Range | 14.65 - 40.00 |
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...
Frequency Therapeutics (FREQ) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Find Strong Stocks with this New Analyst Coverage Screener
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...
Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients. Progenitor cells are found all throughout the...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage ...
Frequency Therapeutics Has A Strong Scientific Rationale And An Upcoming Binary Catalyst
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
These strong stocks to buy benefited from atypical and big insider buying activity over the past few weeks. The post 5 Stocks to Buy Because of Heavy Insider Buying in July appeared first on ...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
Frequency Therapeutics: FX-322 Top Line Data From Exploratory Study Proves Promising
While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.
Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?
Frequency Therapeutics (NASDAQ: FREQ) made its public debut Thursday morning, opening at $11.20 after being priced at $14 per share.
About FREQ
Frequency Therapeutics, a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of ... [Read more...]
| Industry Biotechnology | IPO Date Oct 3, 2019 |
| CEO David L. Lucchino | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol FREQ |
Analyst Forecasts
According to 5 analysts, the average rating for FREQ stock is "Buy." The 12-month stock price forecast is 47.00, which is an increase of 21.35% from the latest price.